Articles

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between January 27, 2023, and March 22, 2023. Read More ›

Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist. Read More ›

A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results. Read More ›

Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer. Read More ›

Evaluation of flat-dose nivolumab plus weight-based ipilimumab in patients with advanced non–small-cell lung cancer and poorer prognosis demonstrates efficacy with a tolerable safety profile. Read More ›

A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation. Read More ›

A recent study from the United Kingdom in younger adults with non–small-cell lung cancer found poor survival outcomes in patients without targetable mutations. Read More ›

Based on positive results of the KRYSTAL-1 clinical trial, adagrasib was granted accelerated FDA approval for patients with non–small-cell lung cancer harboring the KRAS G12C mutation. Read More ›

A recent study assessing the prognostic value of circulating tumor cells in patients with lung cancer found an association with poorer patient outcomes, with more pronounced effect on small-cell lung cancer. Read More ›

This edition of Year in Review is focused on multiple myeloma (MM), a disease for which the treatment landscape has seen tremendous growth resulting in major favorable changes in patient outcomes. New treatments have been approved and novel classes of agents continue to be investigated, particularly in the relapsed/refractory multiple myeloma (RRMM) setting. We are providing this Year in Review series to disseminate the latest information on treatment advances in 2022 to clinicians in a timely and effective manner. Read More ›